Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:15189029rdf:typepubmed:Citationlld:pubmed
pubmed-article:15189029lifeskim:mentionsumls-concept:C1749467lld:lifeskim
pubmed-article:15189029lifeskim:mentionsumls-concept:C1449701lld:lifeskim
pubmed-article:15189029lifeskim:mentionsumls-concept:C1441547lld:lifeskim
pubmed-article:15189029lifeskim:mentionsumls-concept:C1522492lld:lifeskim
pubmed-article:15189029lifeskim:mentionsumls-concept:C1743100lld:lifeskim
pubmed-article:15189029lifeskim:mentionsumls-concept:C0599219lld:lifeskim
pubmed-article:15189029pubmed:issue13lld:pubmed
pubmed-article:15189029pubmed:dateCreated2004-6-10lld:pubmed
pubmed-article:15189029pubmed:abstractTextRecent studies have indicated that the most important role of beta-amyloid peptide (Abeta) in the etiology of Alzheimer's disease may not be in plaque formation but in the formation of soluble, metastable Abeta(1-42) neurotoxic intermediates (called ADDLs). In the present work we describe the preparation of per-6-amino-6-deoxy-beta-cyclodextrins, which inhibit ADDLs formation in vitro.lld:pubmed
pubmed-article:15189029pubmed:languageenglld:pubmed
pubmed-article:15189029pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15189029pubmed:citationSubsetIMlld:pubmed
pubmed-article:15189029pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15189029pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15189029pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15189029pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15189029pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15189029pubmed:statusMEDLINElld:pubmed
pubmed-article:15189029pubmed:monthJunlld:pubmed
pubmed-article:15189029pubmed:issn0022-2623lld:pubmed
pubmed-article:15189029pubmed:authorpubmed-author:KleinWilliam...lld:pubmed
pubmed-article:15189029pubmed:authorpubmed-author:WangZhiqiangZlld:pubmed
pubmed-article:15189029pubmed:authorpubmed-author:ChangLeiLlld:pubmed
pubmed-article:15189029pubmed:authorpubmed-author:ThatcherGrego...lld:pubmed
pubmed-article:15189029pubmed:authorpubmed-author:VentonDuane...lld:pubmed
pubmed-article:15189029pubmed:issnTypePrintlld:pubmed
pubmed-article:15189029pubmed:day17lld:pubmed
pubmed-article:15189029pubmed:volume47lld:pubmed
pubmed-article:15189029pubmed:ownerNLMlld:pubmed
pubmed-article:15189029pubmed:authorsCompleteYlld:pubmed
pubmed-article:15189029pubmed:pagination3329-33lld:pubmed
pubmed-article:15189029pubmed:dateRevised2010-11-18lld:pubmed
pubmed-article:15189029pubmed:meshHeadingpubmed-meshheading:15189029...lld:pubmed
pubmed-article:15189029pubmed:meshHeadingpubmed-meshheading:15189029...lld:pubmed
pubmed-article:15189029pubmed:meshHeadingpubmed-meshheading:15189029...lld:pubmed
pubmed-article:15189029pubmed:meshHeadingpubmed-meshheading:15189029...lld:pubmed
pubmed-article:15189029pubmed:meshHeadingpubmed-meshheading:15189029...lld:pubmed
pubmed-article:15189029pubmed:meshHeadingpubmed-meshheading:15189029...lld:pubmed
pubmed-article:15189029pubmed:year2004lld:pubmed
pubmed-article:15189029pubmed:articleTitlePer-6-substituted-per-6-deoxy beta-cyclodextrins inhibit the formation of beta-amyloid peptide derived soluble oligomers.lld:pubmed
pubmed-article:15189029pubmed:publicationTypeLetterlld:pubmed
pubmed-article:15189029pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...http://linkedlifedata.com/r...pubmed-article:15189029lld:chembl
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15189029lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15189029lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15189029lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15189029lld:pubmed